Hypoxia-inducible lipid droplet-associated (HILPDA) is a novel peroxisome proliferator-activated receptor (PPAR) target involved in hepatic triglyceride secretion
scar tissue formation at the injury site Anti-inflammatory down-regulates NF-B signaling, one of the key inflammatory pathways active in disc herniations Works in synergy with BPC-157 while BPC-157 creates the growth signals, TB-500 provides the cellular migration framework to execute the repair Protocol: Loading phase: 2.5mg5mg/week subcutaneous injection for 46 weeks Maintenance: 1.252.5mg/week ongoing Frequency: Single weekly injection or split into two 1.25mg injections across the week (both approaches work) The Synergy: Why Run Both Together BPC-157 and TB-500 work through different but complementary mechanisms
Prandial timing matters more for gastric modulators (amylin analogues, GLP-1 agonists) than for systemic metabolic agents
B12 supplementation will only help your hair if deficiency is genuinely contributing to the problem
Systemic Use Systemic or injectable use should never occur without medical oversight and established clinical evidence
Animal studies used several routes: intraperitoneal, intramuscular, intravenous, and oral